Holen Sie sich die Stockscreener-App
1.07
3.88%
0.04
Handel nachbörslich:
1.05
-0.02
-1.87%
Schlusskurs vom Vortag:
$1.03
Offen:
$1.06
24-Stunden-Volumen:
268.24K
Relative Volume:
0.37
Marktkapitalisierung:
$79.23M
Einnahmen:
$8.23M
Nettoeinkommen (Verlust:
$-32.49M
KGV:
-1.8136
EPS:
-0.59
Netto-Cashflow:
$-19.91M
1W Leistung:
+1.90%
1M Leistung:
-26.21%
6M Leistung:
-18.32%
1J Leistung:
+12.03%
1-Tages-Spanne:
$1.05
$1.09
1-Wochen-Bereich:
$0.99
$1.09
52-Wochen-Spanne:
$0.7564
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Firmenname
Clearside Biomedical Inc
Sektor
Branche
Telefon
678-270-3631
Adresse
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-15 | Fortgesetzt | Wedbush | Outperform |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-09 | Herabstufung | Needham | Buy → Hold |
| 2018-11-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2018-11-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-06 | Bestätigt | Needham | Buy |
| 2017-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-10-24 | Bestätigt | Stifel | Buy |
Alle ansehen
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Clearside Biomedical (CLSD) to Release Earnings on Tuesday - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Insider Purchases $36,500.00 in Stock - MarketBeat
Clearside Biomedical chief medical officer buys $36,500 in stock - Investing.com
Clearside Biomedical chief medical officer buys $36,500 in stock By Investing.com - Investing.com UK
Clearside Biomedical names new board chair By Investing.com - Investing.com Australia
Clearside Biomedical names new board chair - Investing.com
Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors - GlobeNewswire
Clearside Biomedical to Report Third Quarter 2024 Financial - GlobeNewswire
Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024 - StockTitan
Clearside’s CLS-AX shows promise in treatment of wet age-related macular degeneration - 2 Minute Medicine
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.17 - MarketBeat
Short Interest in Clearside Biomedical, Inc. (NASDAQ:CLSD) Rises By 646.6% - MarketBeat
Clearside Biomedical advances CLS-AX into Phase 3 trials By Investing.com - Investing.com Nigeria
Clearside Biomedical Inc Still Hasn’t Convinced Analysts? - Stocks Register
Clearside Biomedical advances CLS-AX into Phase 3 trials - Investing.com
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting - ForexTV.com
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and - GlobeNewswire
Clearside Biomedical (NASDAQ:CLSD) Stock Rating Upgraded by StockNews.com - Defense World
Clearside Biomedical (NASDAQ:CLSD) Rating Increased to Hold at StockNews.com - MarketBeat
Healthy Upside Potential: Clearside Biomedical Inc (CLSD) - SETE News
Investing in Clearside Biomedical Inc (CLSD): What You Must Know - Knox Daily
Clearside Biomedical (NASDAQ:CLSD) Stock Rating Reaffirmed by Chardan Capital - MarketBeat
Ratio Analysis: Unpacking Clearside Biomedical Inc (CLSD)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Results from Clearside Biomedical Inc (CLSD) show risk - US Post News
CLSD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Clearside Biomedical Inc [NASDAQ: CLSD] Sees Increase in Stock Value - Knox Daily
How does Clearside Biomedical Inc (CLSD) change from a tortoise to a hare? - SETE News
Needham & Company LLC Raises Clearside Biomedical (NASDAQ:CLSD) Price Target to $6.00 - MarketBeat
Clearside stock falls 12% amid Phase 2 data for CLS-AX - MSN
Clearside Biomedical's Stock (CLSD) Dips On Trial Despite Reiterated Confidence From Analyst - AskTraders
Clearside’s wet AMD drug-device combo shines in Phase IIb study - Clinical Trials Arena
Financial Metrics Unveiled: Clearside Biomedical Inc (CLSD)’s Key Ratios in the Spotlight - The Dwinnex
Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD - Scrip
Clearside stock falls 12% amid Phase 2 data for CLS-AX (NASDAQ:CLSD) - Seeking Alpha
Traders Buy Large Volume of Call Options on Clearside Biomedical (NASDAQ:CLSD) - MarketBeat
Clearside Biomedical's Investigational Drug For Vision Loss Hits Primary Goals In Mid-Stage Study - Yahoo Finance
Clearside Biomedical (NASDAQ:CLSD) Files 8-K with the SEC Regarding Latest Developments - MarketBeat
Clearside Biomedical’s Promising Phase 2b ODYSSEY Trial Outcomes - TipRanks
A stock that deserves closer examination: Clearside Biomedical Inc (CLSD) - US Post News
Top Premarket Gainers - Marketscreener.com
Clearside reports success in wet AMD trial - Investing.com
Clearside Biomedical Announces Positive Topline Results - GlobeNewswire
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes - Yahoo Finance
CLSD’s latest rating updates from top analysts. - Knox Daily
CLSD’s Market Whiplash: 35.04% YTD Rise, 62.89% Rise in 30 Days - The InvestChronicle
Analyst Forecast For Clearside Biomedical Inc (NASDAQ: CLSD) - Stocks Register
What is Clearside Biomedical Inc (CLSD) Stock Return on Shareholders’ Capital? - SETE News
Financial Analysis: Clearside Biomedical Inc (CLSD)’s Ratios Unveil Key Insights - The Dwinnex
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of "Buy" by Brokerages - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts - Defense World
CLSD overperforms with a 5.51 increase in share price - US Post News
Finanzdaten der Clearside Biomedical Inc-Aktie (CLSD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):